文献速递垂体与肾上腺疾病肥胖与代谢综合征

Silver-Russell综合征患者代谢健康与生长激素治疗的长期安全性

Metabolic Health and Long-Term Safety of Growth Hormone Treatment in Silver-Russell Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

该研究纵向评估29例Silver-Russell综合征(SRS)患者与171例非SRS小于胎龄儿(SGA)在生长激素(GH)治疗期间及停药后2年的代谢健康。两组在GH启动时血压、血脂、血糖和胰岛素水平相似且正常,治疗期间及停药后瘦体重与脂肪百分比变化趋势相似,停药2年后所有参数均正常且无代谢综合征、2型糖尿病或不良事件发生。结论认为GH治疗的SRS患者代谢健康与安全性与非SRS的SGA儿童相似。

要点

  • GH启动时SRS与非SRS的SGA儿童血压、血脂、血糖和胰岛素水平相似且正常。
  • 治疗期间两组瘦体重SDS保持稳定而脂肪百分比SDS增加,停药后瘦体重下降、脂肪百分比增加。
  • 停药2年后所有代谢参数在两组均正常,SRS患者无代谢综合征、2型糖尿病或不良事件。

核心结论

  • GH治疗的SRS患者在治疗期间及停药后2年内代谢健康与安全性与非SRS的SGA儿童相似。

研究设计与样本

  • 纵向评估代谢健康于GH启动时、GH停止时、停药后6个月和2年进行。
  • 纳入29例SRS患者与171例非SRS的SGA儿童进行对比。

主要发现

  • GH启动时平均年龄(标准差)SRS为5.4(2.1)岁,非SRS为6.7(2.0)岁(P=0.003)。
  • GH启动时两组血压、血脂、血糖和胰岛素水平相似且处于正常范围。
  • GH启动时两组瘦体重标准差评分(SDS)和脂肪百分比SDS均低于平均水平。
  • 治疗期间两组瘦体重SDS保持稳定,脂肪百分比SDS增加。
  • 停药后2年内瘦体重下降、脂肪百分比增加,胰岛素敏感性和β细胞功能改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Children with Silver-Russell syndrome (SRS) are born small for gestational age (SGA) and remain short. Growth hormone (GH) treatment improves height in short SGA children, including those with SRS. Data on metabolic health and long-term safety of GH treatment in SRS are lacking. OBJECTIVE: To investigate metabolic health in SRS patients during and until 2 years after discontinuation of GH treatment. DESIGN: Metabolic health was assessed longitudinally at GH-start, GH-stop, 6 months, and 2 years thereafter. PATIENTS: Twenty-nine SRS patients vs 171 non-SRS subjects born SGA. MAIN OUTCOME MEASURES: Lean body mass (LBM), fat mass percentage (FM%), insulin sensitivity (Si), β-cell function, blood pressure, and serum lipids. RESULTS: At GH-start [mean age (standard deviation) 5.4 (2.1) years in SRS and 6.7 (2.0) years in non-SRS (P = 0.003)], blood pressure, serum lipids, glucose, and insulin levels were similar and within normal ranges in SRS and non-SRS. LBM standard deviation score (SDS) and FM% SDS were lower than average in both groups. During treatment, LBM SDS remained stable whereas FM% SDS increased in both groups. During the 2 years after GH-stop, LBM decreased and FM% increased, whereas Si and β-cell function improved. At 2 years after GH-stop (mean age 18 years), all parameters were similar and within normal ranges in SRS and non-SRS. None of the SRS patients developed metabolic syndrome, diabetes mellitus type 2, or adverse events. CONCLUSION: GH-treated SRS patients have a similar metabolic health and safety profile as non-SRS subjects born SGA, both during and until 2 years after GH-stop.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Smeets CC, Renes JS, van der Steen M, et al. Metabolic Health and Long-Term Safety of Growth Hormone Treatment in Silver-Russell Syndrome. J Clin Endocrinol Metab. 2017. PMID: 28001454. doi:10.1210/jc.2016-3388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。